|2-Trifluoromethyl-2'-methoxychalcone Nrf2 activator|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Cas No.||1309371-03-6||SDF||Download SDF|
|Solubility||Soluble in DMSO||Storage||Store at -20°C|
|Shipping Condition||Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
2-Trifluoromethyl-2'-methoxychalcone is a Nrf2 activator.
Nrf2-mediated activation of antioxidant response element is a key process of molecular mechanisms regulating the protective function of phase II detoxification and antioxidant enzymes against oxidative stress, carcinogenesis, and inflammation.
In vitro: The expression of luciferase gene under the control of NQO1-ARE sequence was measured using stably transfected Beas-2B cells treated with 2-trifluoromethyl-2'-methoxychalcone. Results showed that the exposure to 2-trifluoromethyl-2'-methoxychalcone led to a significant concentration-dependent increase in luciferase activity. Moreover, Beas-2B cells were coincubated with 2-trifluoromethyl-2'-methoxychalcone and with or without N-acetylcysteine, and it was found that 2-trifluoromethyl-2'-methoxychalcone could potentially increase the expression of Nr2-regulated antioxidant genes in the presence of N-acetylcysteine .
In vivo: C57BL/6 mice were treated with a single dose of vehicle or 2-trifluoromethyl-2'-methoxychalcone or sulforaphane as the positive control, and small intestines were harvested 24 h later. Results showed that the expression of GCLM and NQO1 in the small intestine of mice treated with 2-trifluoromethyl-2'-methoxychalcone was 6-fold and 10-fold higher compared to vehicle, respectively. In addition, the expression of GCLM and NQO1 in the small intestine treated with 2-trifluoromethyl-2'-methoxychalcone was 3-fold and 5-fold higher compared to sulforaphane, respectively .
Clinical trial: Up to now, 2-trifluoromethyl-2'-methoxychalcone is still in the preclinical development stage.
 V. Kumar, S. Kumar, M. Hassan, et al. Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells. Journal of Medicinal Chemistry 54(12), 4147-4159 (2011).